Straits Times Index
3,264.53 -35.51 (-1.08%) S&P 500
5,183.23 -4.47 (-0.09%) Dow
38,956.52 +72.26 (+0.19%) Nasdaq
16,291.11 -41.45 (-0.25%) Bitcoin USD
62,087.13 -1,723.61 (-2.70%) CMC Crypto 200
1,325.46 +30.79 (+2.38%)
Pfizer Inc. (PFE)
| Previous close | 27.77 |
| Open | 27.70 |
| Bid | 28.21 x 4000 |
| Ask | 28.22 x 3100 |
| Day's range | 27.52 - 28.23 |
| 52-week range | 25.20 - 40.37 |
| Volume | |
| Avg. volume | 42,456,437 |
| Market cap | 159.599B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.05 |
| Earnings date | 30 Jul 2024 - 05 Aug 2024 |
| Forward dividend & yield | 1.68 (6.05%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | 31.37 |
- Reuters
UPDATE 1-Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports
Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the deal. The agreements cover cases in U.S. state courts but don't completely resolve the company's exposure to Zantac claims, the report said, adding that financial details of the deals were not immediately available. Pfizer did not immediately respond to a Reuters request for comment.
ReutersPfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports
The agreements cover cases in U.S. state courts but don't completely resolve the company's exposure to Zantac claims, the report said, adding that financial details of the deals were not immediately available. Pfizer did not immediately respond to a Reuters request for comment. In 2020, the U.S. Food and Drug Administration asked drugmakers to pull Zantac and its generic versions off the market after a cancer-causing substance called NDMA was found in samples of the drug.
GuruFocus.comPfizer Inc's Dividend Analysis
Pfizer Inc (NYSE:PFE) recently announced a dividend of $0.42 per share, payable on 2024-06-14, with the ex-dividend date set for 2024-05-09. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Pfizer Inc's dividend performance and assess its sustainability.
